- Home
- JANX vs NAD Comparison
JANX vs NAD Comparison
Compare JANX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- NAD
- Stock Information
- Founded
- JANX 2017
- NAD 1999
- Country
- JANX United States
- NAD United States
- Employees
- JANX N/A
- NAD N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- NAD Investment Managers
- Sector
- JANX Health Care
- NAD Finance
- Exchange
- JANX Nasdaq
- NAD Nasdaq
- Market Cap
- JANX 1.6B
- NAD 2.5B
- IPO Year
- JANX 2021
- NAD N/A
- Fundamental
- Price
- JANX $31.05
- NAD $11.17
- Analyst Decision
- JANX Strong Buy
- NAD
- Analyst Count
- JANX 7
- NAD 0
- Target Price
- JANX $94.29
- NAD N/A
- AVG Volume (30 Days)
- JANX 969.3K
- NAD 595.7K
- Earning Date
- JANX 05-06-2025
- NAD 01-01-0001
- Dividend Yield
- JANX N/A
- NAD 4.35%
- EPS Growth
- JANX N/A
- NAD N/A
- EPS
- JANX N/A
- NAD N/A
- Revenue
- JANX $10,588,000.00
- NAD N/A
- Revenue This Year
- JANX N/A
- NAD N/A
- Revenue Next Year
- JANX $250.58
- NAD N/A
- P/E Ratio
- JANX N/A
- NAD N/A
- Revenue Growth
- JANX 30.99
- NAD N/A
- 52 Week Low
- JANX $22.52
- NAD $9.56
- 52 Week High
- JANX $71.71
- NAD $11.64
- Technical
- Relative Strength Index (RSI)
- JANX 55.36
- NAD 46.60
- Support Level
- JANX $27.93
- NAD $11.00
- Resistance Level
- JANX $32.59
- NAD $11.19
- Average True Range (ATR)
- JANX 1.97
- NAD 0.21
- MACD
- JANX 0.74
- NAD 0.03
- Stochastic Oscillator
- JANX 84.75
- NAD 79.39
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.